Neeraj Agarwal, MD, FASCO, Presidential Endowed Chair of 癌症研究 at Huntsman Cancer Institute, professor of medicine 在 University of Utah, 和 lead investigator of the Talapro-2 clinical trial, recently published new results from a study where patients were given a combination of drugs to treat advanced 前列腺癌.
The Talapro-2 study combines two different cancer drugs, enzalutamide 和 talazoparib. Enzalutamide has been used for many years for 前列腺癌, but the addition of talazoparib is new. This combination decreases the risk of cancer progression by 55% in patients with advanced 前列腺癌.
新的研究结果， 发表在 自然医学, share the name with a previous 公共ation in 《大发娱乐》 from earlier this year. However, it is important to know th在se two published studies differ. In Agarwal’s most recent research in 自然Medicine, a larger group of patients was studied. Each of the patients had something in common—a specific genetic mutation in their DNA, known as homologous recombination repair genes (HRR). Previous 公共ations were with much smaller groups of people who did not have these genetic mutations.
According to Agarwal, HRR genes play a crucial role in fixing damaged DNA. When a mutation occurs, these genes are not able to mend the damage, which can lead to an increased risk of developing cancer. These gene mutations can be passed down through families. Scientists found HRR genes using the Utah Population Database (UPDB) at Huntsman Cancer Institute, an in-depth database of family genetic information. The process was similar to the discovery of BRCA1 和 BRCA2.
“Thanks to the large families who contributed their vast genetic history to this database, we have been able to use this information, 年后, to help a specific group of patients with advanced 前列腺癌,阿加瓦尔说.
Out of 1,037名患者, many had the BRCA genetic mutation, which increases the risk of developing breast, 卵巢, or 前列腺癌. Other participants had CHEK2, CDK12, ATM, or a combination of mutations. These specific patients had even greater success from the drug combination than the general patient population in previous 公共ations.
“There was a significant delay in needing chemotherapy 和 disease progression,阿加瓦尔说. “This is a huge benefit to these patients, both physically 和 psychologically.”
Agarwal is a huge advocate for cancer research 和 has led more than 400 articles to 公共ation. He is the senior director for clinical research translation, which oversees many 早期 和 advanced phase clinical trials.
媒体接触
希瑟·西蒙森
Public Affairs Senior Manager
Huntsman Cancer Institute
801 581-3194
公共.affairs@hci.犹他州.edu
About Huntsman Cancer Institute 在 University of Utah
Huntsman Cancer Institute 在 University of Utah is the National Cancer Institute-designated Comprehensive Cancer Center for Utah, 爱达荷州, 蒙大拿, 内华达, 和怀俄明州. With a legacy of innovative cancer research, groundbreaking discoveries, 和 world-class patient care, we are transforming the way cancer is understood, 预防, 诊断, 治疗, 并存活下来. Huntsman Cancer Institute focuses on delivering the most advanced cancer healing 和 prevention through scientific breakthroughs 和 cutting-edge technology to advance cancer treatments of the future beyond the st和ard of care today. We have more than 300 open clinical trials 和 250 research teams 研究癌症. More genes for inherited cancers have been discovered at Huntsman Cancer Institute than at any other cancer center. Our scientists are world-renowned for underst和ing how cancer begins 和 using that knowledge to develop innovative approaches to treat each patient’s unique disease. Huntsman Cancer Institute was founded by Jon M. 和 Karen Huntsman.